Monsenso issues warrants to the deputy chairman of the board

23.5.2024 16:48:37 CEST | Monsenso | Company Announcement

Company announcement no. 13-2024

Copenhagen, 2024.05.23

This message includes inside information.

The Board of Directors of Monsenso announces the decision to issue warrants to the deputy chairman of the board Kaspar R Kristiansen, following § 5.3 of the articles of association and, at the same time, it is announced that company announcement no. 12-2024 is canceled due to the program has not been implemented.

The vesting period for the warrants is 12 months from 1 May 2024 to 30 April 2025, but only if the recipient is still a board member. Unexercised warrants expire on 31 August 2031. DKK 1,662,616 warrants have been granted, giving the right to subscribe for a nominal DKK 166,261.60 shares in the company.

The Board of Directors has set the exercise price at DKK 0.36 per warrant, corresponding to the market rate calculated as a 90-day closing price and following § 5.3 of the company's articles of association. The closing price on May 22, 2024, was DKK 0.436 per share.

The warrant holder shall not pay any compensation for granting the warrants. The vested warrants can be exercised twice a year after publication of the company's annual and half-yearly report in a utilization window of currently 2 weeks.

Kaspar R. Kristiansen is awarded the above warrants as remuneration for his work in developing a business model for the company with growth and profitability in mind.

According to “Black & Scholes”, the value of the entire Warrant program can be calculated at TDKK 250 and is in line with the company's remuneration policy.

Monsenso's share capital amounts to a nominal value of DKK 6,650,462.90 divided into 66,504,629 shares of DKK 0.10.

Any inquiries regarding this notice should be directed to:

Monsenso

CEO
Thomas Lethenborg
Tel. [phone]
E-mail: [e-mail] 

Chairman of the board
Peter Mørch Eriksen
E-mail: [e-mail]

Certified Adviser

Norden CEF A/S
John Norden

E-mail: [e-mail]

About Monsenso

Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com

Attachments

• Download announcement as PDF.pdf

© Ritzau Denmark, source Ritzau English Regulatory Releases